Clinical ’Omes

Report provides primer on using clinical genome and exome sequencing technologies.

Written byRina Shaikh-Lesko
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, GEORGE GASTINIn a review article published this week (June 19) in the New England Journal of Medicine, researchers have released guidelines on clinical genome and exome sequencing in order provide doctors with a basic outline of the rapidly advancing technologies now available. Coauthors Leslie Biesecker from the National Human Genome Research Institute (NHGRI) and Robert Green of Brigham and Women’s Hospital and Harvard Medical School noted that, in previous years, thousands of physicians have already ordered such sequencing tests. The pair predicted that, this year, another 10,000 tests would be ordered.

“It’s come much faster and developed more quickly and become more useful clinically than I think any reasonable person would have suggested just 10 years ago,” Biesecker said in a statement. “At that time, I don’t think anybody would have taken you seriously if you had said that in 2014, tens of thousands of patients would be getting clinical genome and exome sequencing.”

Today, clinical genome and exome sequencing technologies work best for patients with rare disorders that are caused by single gene variants. Only about 25 percent of tests will identify a single-gene variant, however. And diagnosis may not lead to treatment, especially for rare conditions. The authors noted that counseling patients is essential as the tests may not be appropriate for all patients. ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
July Digest 2025
July 2025, Issue 1

What Causes an Earworm?

Memory-enhancing neural networks may also drive involuntary musical loops in the brain.

View this Issue
Genome Modeling and Design: From the Molecular to Genome Scale

Genome Modeling and Design: From the Molecular to Genome Scale

Twist Bio 
Screening 3D Brain Cell Cultures for Drug Discovery

Screening 3D Brain Cell Cultures for Drug Discovery

Discover how to streamline tumor-infiltrating lymphocyte production.

Producing Tumor-infiltrating Lymphocyte Therapeutics

cytiva logo
Explore synthetic DNA’s many applications in cancer research

Weaving the Fabric of Cancer Research with Synthetic DNA

Twist Bio 

Products

The Scientist Placeholder Image

Sino Biological Sets New Industry Standard with ProPure Endotoxin-Free Proteins made in the USA

sartorius-logo

Introducing the iQue 5 HTS Platform: Empowering Scientists  with Unbeatable Speed and Flexibility for High Throughput Screening by Cytometry

parse_logo

Vanderbilt Selects Parse Biosciences GigaLab to Generate Atlas of Early Neutralizing Antibodies to Measles, Mumps, and Rubella

shiftbioscience

Shift Bioscience proposes improved ranking system for virtual cell models to accelerate gene target discovery